A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Triple-Negative Breast Cancer
Interventions
DRUG

BEBT-209 capsules

BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.

DRUG

Carboplatin injection

Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.

DRUG

Gemcitabine hydrochloride for injection

Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.

Trial Locations (2)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

510120

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY